Lonza revenue was CHF4.51 b in FY, 2020 which is a (23.9%) year over year decrease from the previous period.
Lonza revenue breakdown by business segment: 25.8% from Capsules & Health Ingredients, 48.0% from Biologics, 15.5% from Small Molecules and 10.8% from Cell & Gene
|FY, 2020||FY, 2019||FY, 2018|
|Specialty Ingredients||CHF1.71 b||CHF2.39 b|
|Pharma & Biotech||CHF4.18 b||CHF3.11 b|
|Corporate||CHF60 m||CHF38 m|
|Capsules & Health Ingredients||1.15 b|
|Small Molecules||692 m|
|Cell & Gene||481 m|
|FY, 2019||FY, 2018|
|Latin America||CHF82 m|
|North and Central America||CHF2.61 b|
|Australia & New Zealand||CHF78 m|
|South Africa||CHF10 m|
|Other Countries||CHF5 m|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.